Bruce66423 shares a report from the Associated Press: A rape victim whose DNA from her sexual assault case was used by San Francisco police to arrest her in an unrelated property crime on Monday filed a lawsuit against the city. During a search of a San Francisco Police Department crime lab database, the woman's DNA was tied to a burglary in late 2021. Her DNA had been collected and stored in the system as part of a 2016 domestic violence and sexual assault case, then-District Attorney Chesa Boudin said in February in a shocking revelation that raised privacy concerns. "This is government overreach of the highest order, using the most unique and personal thing we have -- our genetic code -- without our knowledge to try and connect us to crime," the woman's attorney, Adante Pointer, said in a statement.

The revelation prompted a national outcry from advocates, law enforcement, legal experts and lawmakers. Advocates said the practice could affect victims' willingness to come forward to law enforcement authorities. Federal law already prohibits the inclusion of victims' DNA in the national Combined DNA Index System. There is no corresponding law in California to prohibit local law enforcement databases from retaining victims' profiles and searching them years later for entirely different purposes.

Boudin said the report was found among hundreds of pages of evidence against a woman who had been recently charged with a felony property crime. After learning the source of the DNA evidence, Boudin dropped the felony property crime charges against the woman. The police department's crime lab stopped the practice shortly after receiving a complaint from the district attorney's office and formally changed its operating procedure to prevent the misuse of DNA collected from sexual assault victims, Police Chief Bill Scott said. Scott said at a police commission meeting in March that he had discovered 17 crime victim profiles, 11 of them from rape kits, that were matched as potential suspects using a crime victims database during unrelated investigations. Scott said he believes the only person arrested was the woman who filed the lawsuit Monday.

Elizabeth Holmes -- the founder of blood testing startup Theranos and the poster child for misleading investors, media, and innocent people looking for medical care through a web of deceit -- wants a do-over. She is requesting a new trial, according to a document filed Tuesday in the Southern District Court of California. Gizmodo reports: The motion for a new trial, authored by Holmes' attorneys, hinges on "newly discovered evidence," specifically: the alleged testimony regrets of Adam Rosendorff. Rosendorff was a lab director at Theranos and later, testified as a key witness in the case against Holmes and her ex-boyfriend/partner in crime Ramesh "Sunny" Balwani. His original testimony lasted multiple days and emphasized the pressure that Theranos employees were under to demonstrate the faulty diagnostic technology worked, even when it didn't.

"I felt that it was a question on my integrity as a physician not to remain there and to continue to bolster results I essentially didn't have faith in," Rosendorff said while on the witness stand in 2021, according to CNBC. "I came to understand that management was not sincere in diverting resources to solve issues." Now, Holmes and her lawyers are claiming that Rosendorff left a voicemail and then showed up at Holmes' residence on August 8 in a desperate bid to communicate that he "felt he had done something wrong, apparently in connection with Ms. Holmes' trial." The motion, supposedly paraphrasing Rosendorff, says that the former Theranos employee stated, "the government made things seem worse than they were."

In the document, Holmes' legal team wrote, "Under any interpretation of his statements, the statements warrant a new trial under Rule 33. But, at a minimum, and to the extent the Court has any doubt about whether a new trial is required, the Court should order an evidentiary hearing and permit Ms. Holmes to subpoena Dr. Rosendorff to testify about his concerns." Holmes was found guilty in January on four of 11 charges defrauding the company's investors and patients. She was found not guilty on four counts.

In July, Balwani was found guilty of 12 counts of conspiracy and fraud against certain investors and patients.

A federal judge on Thursday tentatively declined to overturn the jury conviction of disgraced Theranos CEO Elizabeth Holmes on four felony counts of fraud and conspiracy. That leaves the former Silicon Valley star a step closer to serving prison time. Politico reports: U.S. District Judge Edward Davila won't make that decision final until Oct. 17, when he is scheduled to sentence Holmes in the same San Jose, California, courtroom where a jury found her guilty of duping investors in her much-hyped blood-testing startup. Holmes, 38, faces up to 20 years in prison and a $250,000 fine, plus restitution, for lying to investors about a Theranos technology she hailed as a revolution in healthcare but which in practice produced dangerously inaccurate results.

An anonymous reader quotes a report from The Associated Press: Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat. Lyme is a growing problem, with cases rising and warming weather helping ticks expand their habitat. While a vaccine for dogs has long been available, the only Lyme vaccine for humans was pulled off the U.S. market in 2002 from lack of demand, leaving people to rely on bug spray and tick checks. Now Pfizer and French biotech Valneva are aiming to avoid previous pitfalls in developing a new vaccine to protect both adults and kids as young as 5 from the most common Lyme strains on two continents.

Most vaccines against other diseases work after people are exposed to a germ. The Lyme vaccine offers a different strategy -- working a step earlier to block a tick bite from transmitting the infection, said Dr. Gary Wormser, a Lyme expert at New York Medical College who isn't involved with the new research. How? It targets an "outer surface protein" of the Lyme bacterium called OspA that's present in the tick's gut. It's estimated a tick must feed on someone for about 36 hours before the bacteria spreads to its victim. That delay gives time for antibodies the tick ingests from a vaccinated person's blood to attack the germs right at the source.

In small, early-stage studies, Pfizer and Valneva reported no safety problems and a good immune response. The newest study will test if the vaccine, called VLA15, really protects and is safe. The companies aim to recruit at least 6,000 people in Lyme-prone areas including the Northeast U.S. plus Finland, Germany, the Netherlands, Poland and Sweden. They'll receive three shots, either the vaccine or a placebo, between now and next spring's tick season. A year later, they'll get a single booster dose.

Live and high-resolution images of a patient's internal organs are already possible with ultrasound imaging technology. But currently the technology "requires bulky and specialized equipment available only in hospitals and doctor's offices," explains an annoncement from MIT.

Now a new design by MIT engineers "might make the technology as wearable and accessible as buying Band-Aids at the pharmacy." In a paper appearing today in Science, the engineers present the design for a new ultrasound sticker — a stamp-sized device that sticks to skin and can provide continuous ultrasound imaging of internal organs for 48 hours.

The researchers applied the stickers to volunteers and showed the devices produced live, high-resolution images of major blood vessels and deeper organs such as the heart, lungs, and stomach. The stickers maintained a strong adhesion and captured changes in underlying organs as volunteers performed various activities, including sitting, standing, jogging, and biking....

From the stickers' images, the team was able to observe the changing diameter of major blood vessels when seated versus standing. The stickers also captured details of deeper organs, such as how the heart changes shape as it exerts during exercise. The researchers were also able to watch the stomach distend, then shrink back as volunteers drank then later passed juice out of their system. And as some volunteers lifted weights, the team could detect bright patterns in underlying muscles, signaling temporary microdamage.

"With imaging, we might be able to capture the moment in a workout before overuse, and stop before muscles become sore," says Chen. "We do not know when that moment might be yet, but now we can provide imaging data that experts can interpret."
They're already envisioning other possibilities: If the devices can be made to operate wirelessly — a goal the team is currently working toward — the ultrasound stickers could be made into wearable imaging products that patients could take home from a doctor's office or even buy at a pharmacy. "We envision a few patches adhered to different locations on the body, and the patches would communicate with your cellphone, where AI algorithms would analyze the images on demand," says the study's senior author, Xuanhe Zhao, professor of mechanical engineering and civil and environmental engineering at MIT.

"We believe we've opened a new era of wearable imaging: With a few patches on your body, you could see your internal organs."

"In what's being hailed as an important first for chemistry, an international team of scientists has developed a new technology that can selectively rearrange atomic bonds within a single molecule," reports New Atlas. "The breakthrough allows for an unprecedented level of control over chemical bonds within these structures, and could open up some exciting possibilities in what's known as molecular machinery."

"Selective chemistry — the ability to steer reactions at will and to form exactly the chemical bonds you want and no others — is a long-standing quest in chemistry," adds the announcement from IBM Research. "Our team has been able to achieve this level of selectivity in tip-induced redox reactions using scanning probe microscopy." Our technique consisted in using the tip of a scanning probe microscope to apply voltage pulses to single molecules. We were able to target specific chemical bonds in those molecules, breaking those bonds and forging new, different ones to switch back and forth at will among three different molecular structures.

The molecules in our experiment all consisted of the same atoms, but differed in the way those atoms were bonded together and arranged in space... Our findings were published today and featured on the cover of Science.

Our demonstration of selective and reversible formation of intramolecular covalent bonds is unprecedented. It advances our understanding of chemical reactions and opens a route towards advanced artificial molecular machines.... Imagine one could rearrange bonds inside a molecule at will, transforming one structural isomer into various other ones in a controlled manner. In this paper, we describe a system and a method to make exactly that possible — including the control of the direction of the atomic rearrangements by means of an external driving voltage, and without the use of reagents.
Thanks to Slashdot reader Grokew for sharing the story!

An anonymous reader quotes a report from Bloomberg: Technology used to develop Covid-19 vaccines may also help combat a honeybee-killing pest. GreenLight Biosciences is developing an RNA-based syrup to attack varroa mites, a parasite that attaches itself to honeybees and feeds off them while spreading diseases. [Varroa mites are thought to be one of the reasons behind the staggeringly high death rates that have become so common among honeybees.] The RNA acts as an "off switch" that interferes with the mites, disrupting their ability to lay offspring that attach to bees, said Mark Singleton, chief commercial officer and general manager of plant health at the Boston-based firm. "We are really putting a dent in the ability of mites to reproduce," he said. Anecdotal feedback shows that hives using his company's treatment are healthier and have a higher survival rate, according to Singleton, whose biotech firm worked with large-scale US beekeepers to test the technology.

Moderna and Pfizer used experimental messenger RNA technology to develop Covid-19 vaccines that instruct the body to make the spike protein the coronavirus uses to enter cells, which in turn stimulates production of antibodies. GreenLight Biosciences acquired the RNA technology from Bayer in 2020 and it is the first RNA regulation that directly targets the mites, which reproduce in the same cells as bee larvae. Unlike chemical options that exist to control the mites, RNA is naturally occurring and degrades without causing any harm to the bees, Singleton said. The product is placed in an envelope with holes that beekeepers put in a hive. The bees do the rest -- ultimately delivering it to where mites produce. GreenLight plans to submit its product for approval to the US Environmental Protection Agency by year end and, if approved, it could be commercially available by 2024.

A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that may foreshadow wide use of the technology to prevent heart attacks. MIT Technology Review reports: The experiment, part of a clinical trial by the US biotechnology company Verve Therapeutics, involved injecting a version of the gene-editing tool CRISPR in order to modify a single letter of DNA in the patient's liver cells. According to the company, that tiny edit should be enough to permanently lower a person's levels of "bad" LDL cholesterol, the fatty molecule that causes arteries to clog and harden with time. The patient in New Zealand had an inherited risk for extra-high cholesterol and was already suffering from heart disease. However, the company believes the same technique could eventually be used on millions of people in order to prevent cardiovascular disease.

In New Zealand, where Verve's clinical trial is taking place, doctors will give the gene treatment to 40 people who have an inherited form of high cholesterol known as familial hypercholesterolemia, or FH. People with FH can have cholesterol readings twice the average, even as children. Many learn they have a problem only when they get hit with a heart attack, often at a young age. The study also marks an early use of base editing, a novel adaptation of CRISPR that was first developed in 2016. Unlike traditional CRISPR, which cuts a gene, base editing substitutes a single letter of DNA for another.

The gene Verve is editing is called PCSK9. It has a big role in maintaining LDL levels and the company says its treatment will turn the gene off by introducing a one-letter misspelling. [...] One reason Verve's base-editing technique is moving fast is that the technology is substantially similar to mRNA vaccines for covid-19. Just like the vaccines, the treatment consists of genetic instructions wrapped in a nanoparticle, which ferries everything into a cell. While the vaccine instructs cells to make a component of the SARS-CoV-2 virus, the particles in Verve's treatment carry RNA directions for a cell to assemble and aim a base-editing protein, which then modifies that cell's copy of PCSK9, introducing the tiny mistake. In experiments on monkeys, Verve found that the treatment lowered bad cholesterol by 60%. The effect has lasted more than a year in the animals and could well be permanent. The report notes that the human experiment does carry some risk. "Nanoparticles are somewhat toxic, and there have been reports of side effects, like muscle pain, in people taking other drugs to lower PCSK9," reports MIT Technology Review. "And whereas treatment with ordinary drugs can be discontinued if problems come up, there's as yet no plan to undo gene editing once it's performed."

Sunny Balwani, the former president and chief operating officer of bankrupt blood-testing company Theranos, on Thursday was found guilty of 12 counts of conspiracy and fraud against certain investors and patients. Axios reports: It's a similar verdict to one handed down in January to Theranos founder and ex-CEO Elizabeth Holmes, who once dated Balwani. Balwani isn't a household name like Holmes, but he was instrumental in building a billion-dollar house of cards that duped both investors and patients. Balwani's attorneys tried to pin the blame for Theranos' failures on Holmes, much as her attorneys had tried to blame Balwani.

As we wrote when the trial began: Holmes tried to thread an incredibly narrow rhetorical needle, denying the existence of fraud while also redirecting blame. Balwani seems to be attempting something similar; claiming he was a savvy executive with lots of past success, but also a naif who was bamboozled by Holmes. But prosecutors, who originally wanted to try the pair together, often used Balwani's own words against him. For example, they presented a text message from Balwani to Holmes that read: "I am responsible for everything at Theranos." One big difference between the trials, however, was that Balwani didn't testify in his own defense.

Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year. From a report: Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations. In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to "provide durable variant protection." The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.

Serhat Gumrukcu faces trial in a purported plot to kill an associate who could have exposed him and derailed a drug-development deal worth millions. From a report: Even as a teenager back in Turkey, Serhat Gumrukcu dazzled audiences. In a 2002 video, he opened one of his magic shows dancing with a cane that appeared to be levitating. He was introduced as a medical student and went by the stage name "Dr. No." A little more than a decade later, not long after Mr. Gumrukcu arrived in the U.S., he had his hand in multimillion-dollar oil and real-estate deals. Yet his best-known venture was in medicine. For a time, he thrilled investors with ideas for groundbreaking treatments and drew special notice from the government's top infectious-disease official, Anthony Fauci. In America, the magician had found a new, more lucrative audience.

Enochian Biosciences co-founded by Mr. Gumrukcu in 2018, paid more than $21 million to companies controlled by Mr. Gumrukcu and his husband for consulting, research and the licensing of potential drugs to treat influenza, hepatitis B, HIV and Covid-19, company financial filings show. "Dr. Gumrukcu is one of those rare geniuses that is not bound by scientific discipline or dogma. He sees connections and opportunities often missed," Enochian Vice Chairman Mark Dybul, now chief executive, said in a 2019 news release about Enochian's licensing of a hepatitis B drug from a company controlled by Mr. Gumrukcu. Mr. Gumrukcu's success as a biotech entrepreneur afforded the purchase last year of an $18.4 million office complex in North Hollywood, a neighborhood in Los Angeles, and, earlier, a $5.5 million house in the Hollywood Hills.

Yet much of what people saw in Mr. Gumrukcu was an illusion he cast, misrepresenting himself and his credentials, according to state and federal authorities, court records, former colleagues and those who have sued and won judgments against him over fraudulent medical and financial dealings. Prosecutors now allege that Mr. Gumrukcu arranged the murder of a business associate, Gregory Davis, who threatened to expose him as a fraud. Such a revelation would have put at risk the 39-year-old entrepreneur's deal with Enochian, they said. Mr. Gumrukcu has been in custody at the Metropolitan Detention Center in Los Angeles since his arrest on May 24. A federal grand jury indicted him on murder conspiracy charges, an offense punishable by death.

"Researchers at Tsinghua University in China have developed a new drug cocktail that can convert cells into totipotent stem cells, the very seeds of life..." writes New Atlas: Not all stem cells are created equal — they sit in a branching hierarchy of differentiation potential. Multipotent stem cells are found in many tissues in adults, where they can turn into a few types of cells associated with that tissue or organ to help healing. A step earlier in the development tree are pluripotent stem cells, which are found in embryos and can become almost any type of cell in the body.

But at the top of the chain sit what are known as totipotent stem cells, which can become any cell in the body as well as supportive tissues like the placenta. These mark the very beginning of development, including the first single cell that forms from a fertilized egg, and they persist for the first few stages of development. After that, the cells differentiate into pluripotent stem cells and further specialize into all the cells of the body as it develops.

In recent years scientists have been able to take adult cells and induce a pluripotent state in them, which forms the basis of research into stem cell regenerative medicine. But in the new study, the Tsinghua team took things a step further, returning pluripotent stem cells to a totipotent state for the first time...

This breakthrough could open up some major new opportunities, the team says. In the long run, scientists could potentially create a living organism straight from a mature cell, sidestepping the need for sperm and eggs. That could help people have children who otherwise couldn't, or aid conservation of endangered species.

The researchers do acknowledge, however, that ethical concerns will no doubt arise.
Thanks to long-time Slashdot reader hackingbear for sharing the news.

An anonymous reader quotes a report from the Guardian: More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey. Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll found that 53% of people support the use of human genome editing to prevent children from developing serious conditions such as cystic fibrosis.

There was less enthusiasm for use of the procedure to prevent milder conditions such as asthma, with only 36% in favor, and to create designer babies, with only a fifth expressing support, but views on the technology differed dramatically with age. Younger generations were far more in favor of designer babies than older people, with 38% of 16- to 24-year-olds and 31% of 25- to 34-year-olds supporting the use of gene editing to allow parents to choose features such as their child's height and eye and hair color. In the UK and many other countries it is illegal to perform genome editing on embryos that are intended for pregnancies, but the restrictions could be lifted if research shows the procedure can safely prevent severe diseases.

The Guardian reports: Scientists have successfully developed a revolutionary cancer treatment that lights up and wipes out microscopic cancer cells, in a breakthrough that could enable surgeons to more effectively target and destroy the disease in patients.

A European team of engineers, physicists, neurosurgeons, biologists and immunologists from the UK, Poland and Sweden joined forces to design the new form of photoimmunotherapy. Experts believe it is destined to become the world's fifth major cancer treatment after surgery, chemotherapy, radiotherapy and immunotherapy. The light-activated therapy forces cancer cells to glow in the dark, helping surgeons remove more of the tumours compared with existing techniques — and then kills off remaining cells within minutes once the surgery is complete. In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help surgeons remove them — and then wiped out those left over. Trials of the new form of photoimmunotherapy, led by the Institute of Cancer Research, London, also showed the treatment triggered an immune response that could prime the immune system to target cancer cells in future, suggesting it could prevent glioblastoma coming back after surgery....

The therapy combines a special fluorescent dye with a cancer-targeting compound. In the trial in mice, the combination was shown to dramatically improve the visibility of cancer cells during surgery and, when later activated by near-infrared light, to trigger an anti-tumour effect.

In 2003, the Human Genome Project finished sequencing every bit of human DNA, remembers MIT News.

"Now, over two decades later, MIT Professor Jonathan Weissman and colleagues have gone beyond the sequence to present the first comprehensive functional map of genes that are expressed in human cells." The data from this project, published online June 9 in Cell, ties each gene to its job in the cell, and is the culmination of years of collaboration on the single-cell sequencing method Perturb-seq.

The data are available for other scientists to use. "It's a big resource in the way the human genome is a big resource, in that you can go in and do discovery-based research," says Weissman, who is also a member of the Whitehead Institute and an investigator with the Howard Hughes Medical Institute....

"I think this dataset is going to enable all sorts of analyses that we haven't even thought up yet by people who come from other parts of biology, and suddenly they just have this available to draw on," says former Weissman Lab postdoc Tom Norman, a co-senior author of the paper.
The announcement credits the single-sequencing tool Perturb-seq and CRISPR-Cas9 genome editing which introduced genetic changes into cells and then captured information about which RNAs expressed (uses single-cell RNA sequencing).

The researchers scaled the method to the entire genome using human blood cancer cell lines and noncancerous cells derived from the retina, ultimately using Perturb-seq across more than 2.5 million cells.

Thanks to Slashdot reader Hmmmmmm for sharing the news.

"In molecular biologist David Sinclair's lab at Harvard Medical School, old mice are growing young again," reports CNN: Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset aging cells in mice to earlier versions of themselves. In his team's first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offspring's.

"It's a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age," said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

"If we reverse aging, these diseases should not happen. We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimer's in your 90s." Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

"This is the world that is coming. It's literally a question of when and for most of us, it's going to happen in our lifetimes," Sinclair told the audience.... Sinclair said his lab has reversed aging in the muscles and brains of mice and is now working on rejuvenating a mouse's entire body.
The article points out that he's building on research by Japan's Dr. Shinya Yamanaka (which in 2007 won a Nobel prize).

But one key caveat: "Studies on whether the genetic intervention that revitalized mice will do the same for people are in early stages, Sinclair said. It will be years before human trials are finished, analyzed and, if safe and successful, scaled to the mass needed for a federal stamp of approval."

Humble Bee Bio is on a mission to create a biodegradable alternative to plastics by synthesizing the biology of bees. TechCrunch reports: While the New Zealand-based company is still at an early stage -- it's about halfway through its proof of concept -- if Humble Bee is successful, its bioplastics are likely to make it into the sustainable textiles industry. Humble Bee, which just raised $3.2 million (NZD $5 million) in convertible notes as part of its Series A, has been studying the Australian masked bee, a type of solitary bee that doesn't make honey, but does make a nesting material for laying larvae in, which has many plastic-like properties. "It's resistant to acids and bases. It's hydrophobic, it's waterproof, it's flame retardant, it's stable up to 240 degrees Celsius," Ryan Graves, Humble Bee's chief technology officer, told TechCrunch. "The idea is, how do we recreate this?"

The team is using a synthetic biology approach that involves going into the bee's genetic code and identifying the genes and proteins responsible for the nesting material. Humble Bee has extracted the code and is trying to recreate it in the laboratory. Next, the company will attempt to synthesize plastic-like materials, focusing on four different types of biomaterials that can be turned into fibers and finishing for fabrics. Humble Bee is aiming for anywhere from March to June 2023 to prove out the concept, at which point the team hopes to scale production using industrial-scale fermentation. "There's a degree of exploration still to go on," said Graves, "The processes are time-intensive and they are challenging. Getting going from code to protein is usually a 12-month process, and then we need to scale it up to get hundreds of grams of the stuff out."

An anonymous reader quotes a report from The Guardian: The building of the world's largest bioreactors to produce cultivated meat has been announced, with the potential to supply tens of thousands of shops and restaurants. Experts said the move could be a "gamechanger" for the nascent industry. The US company Good Meat said the bioreactors would grow more than 13,000 tons of chicken and beef a year. It will use cells taken from cell banks or eggs, so the meat will not require the slaughter of any livestock. There are about 170 companies around the world working on cultured meat, but Good Meat is the only company to have gained regulatory approval to sell its product to the public. It began serving cultivated chicken in Singapore in December 2020.

The creation of Good Meat's 10 new bioreactors is under way, the company says, each of which has a capacity of 250,000 liters and will stand four stories tall, far bigger than any constructed to date. The US site for the facility is due to be finalized within three months and operational in late 2024, reaching 11,800 tons a year by 2026 and 13,700 tons by 2030. The bioreactors are being manufactured as part of an agreement with ABEC, a leading bioprocess equipment manufacturer, which is also making a 6,000-liter bioreactor for Good Meat's Singapore site -- this is scheduled to begin production in early 2023 and will itself be the biggest cultured meat bioreactor installed to date. Cultivated meat has not yet been approved for sale by the US Food and Drug Administration. "Weâ(TM)ve submitted our application," said Josh Tetrick, the chief executive of Good Meatâ(TM)s parent company, Eat Just. "Weâ(TM)ve found the agency to be fully engaged, asking all the questions youâ(TM)d expect, from cell identification to final product. Weâ(TM)d prefer not to try to predict if and when [approval] will occur."

Tetrick also said the company had produced a cell growth serum that does not require the use of bovine fetuses, which were previously widely used.

An anonymous reader quotes a report from The Guardian: Scientists have created genetically edited tomatoes, each containing as much provitamin D3 -- the precursor to vitamin D -- as two eggs or a tablespoon of tuna. Outdoor field trials of the tomatoes are expected to begin in the UK next month, and if successful, could provide an important new dietary source of vitamin D. The tomato plants were created by making tiny changes to an existing tomato gene using an editing technique called Crispr-Cas9. "It's like a pair of molecular tweezers, which you can use to precisely snip out a very small fragment of the gene to enhance a desirable trait in plants a lot quicker than traditional breeding process, and without introducing any foreign DNA from other species," said Jie Li at the John Innes Centre in Norwich, who led the research.

In this case, their focus was an enzyme found in tomato plants that normally converts provitamin D3 into cholesterol. By altering this enzyme, the researchers managed to block this pathway, meaning provitamin D3 accumulated in the tomatoes' fruits and leaves. They calculated that the amount of provitamin D3 in one tomato fruit -- if converted to vitamin D3 -- would be equivalent to levels present in two medium-sized eggs or 28 grams of tuna. To convert this into active vitamin D3, the fruit would still need to be exposed to UVB light, or they could potentially be grown outdoors, something the researchers plan to test in upcoming field trials. The research was published in Nature Plants. "Unlike GMOs, the tomato plants do not contain genes from other organisms and could theoretically have been created through selective breeding -- albeit much more slowly," notes the Guardian. Therefore, they could be allowed under a proposed genetic technology (precision breeding) bill aimed to allow gene-edited plants to be treated differently to genetically modified organisms (GMOs).

The BBC reports on "the next generation of genetic modification technology" — which goes beyond simply introducing a "lab-tweaked gene" into an organism. Instead it introduces a "gene drive" — a lab-tweaked gene "that targets and removes a specific natural gene." if an animal (parent A) that contains a gene drive mates with one that doesn't (parent B), then in the forming embryo that starts to combine their genetic material, parent A's gene drive immediately gets to work. It recognises the natural gene version of itself in the opposite chromosome from parent B, and destroys it, by cutting it out of the DNA chain. Parent B's chromosome then repairs itself — but does so, by copying parent A's gene drive. So, the embryo, and the resulting offspring, are all but guaranteed to have the gene drive, rather than a 50% chance with standard GM — because an embryo takes half its genes from each parent.

Gene drives are created by adding something called Crispr, a programmable DNA sequence, to a gene. This tells it to target the natural version of itself in the DNA of the other parent in the new embryo. The gene drive also contains an enzyme that does the actual cutting.

It is hoped that gene drives can be used to greatly reduce the numbers of malarial mosquitos, and other pests or invasive species.... One organisation at the forefront of this is Target Malaria, which has developed gene drives that stop mosquitos from producing female offspring. This is important for two reasons — only the females bite, and without females, mosquito numbers will plummet. The core aim is to greatly reduce the number of people who die from malaria — of which there were sadly 627,000 in 2020, according to the World Health Organization. It could also slash the economic impact of the disease. With 241 million cases in 2020, mostly in Africa, malaria is estimated to cost the continent $12bn (£9.7bn) in reduced economic output every year....

One of the world's pioneering developers of gene drives is US biologist Kevin Esvelt, an assistant professor at Massachusetts Institute of Technology. He first came up with the technology back in 2013.... Prof Esvelt adds that this technology is being provided by something called "daisy chain". This is where a gene drive is designed to become inert after a few generations. Or halving its spread every generation until it eventually stops. Using this technology he says it is possible to control and isolate the spread of gene drives. "A town could release GM organisms with its boundaries to alter the local population [of a particular organism] while minimally affecting the town next door," he says.
The technology has not been authorized for use "in the wild," the article points out. But there are currently no bans on laboratories researching it.